TGTX says BRIUMVI targets $1B+ run rate amid dosing changes
TGTX says BRIUMVI is on track for a $1 billion run rate, citing expanded marketing and simplified dosing plus subQ formulations. The company also expects higher peak sales than current estimates, backed by patent protection.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.